The effects of a fluoroquinolone on the growth and development of infants.

Gurpinar A., Balkan E., Kilic N. , Kiristioglu İ. , Dogruyol H.

The Journal of international medical research, vol.25, no.5, pp.302-6, 1997 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 5
  • Publication Date: 1997
  • Doi Number: 10.1177/030006059702500508
  • Title of Journal : The Journal of international medical research
  • Page Numbers: pp.302-6


Growth and development were monitored for up to 42 months in nine neonates to whom ciprofloxacin, a fluoroquinolone, was given in the neonatal period at a dosage of 20 mg/kg/day. Ciprofloxacin was used only as a 'life-saving' therapy in cases of sepsis produced by bacterial agents resistant to other antibiotics. Two other groups of nine neonates, matched by birth weight and gestational age, were studied as controls: one group with sepsis, which was effectively treated with cefotaxime and a group of healthy neonates. No statistically significant differences in growth and development between the groups were found during follow-up for 42 months. No osteoarticular problems or joint deformities were observed in the ciprofloxacin group. Ciprofloxacin appears to provide a therapeutic option as a 'life-saving' therapy for newborns with sepsis produced by multiply resistant organisms.